Kenneth Burman, MD
Kenneth Burman, MD, brings vast research experience to his role as director of the Endocrine Section at MedStar Washington Hospital Center, having published more than 375 research studies on thyroid cancer and other topics in endocrinology.
Dr. Burman is a professor of medicine and chief of the Integrated Endocrine Fellow Training Program, MedStar Georgetown University Hospital and MedStar Washington Hospital Center, as well as professor of Medicine of the Uniformed Services University of the Health Sciences. He has participated in both clinical and translational thyroid research for nearly 30 years and has produced more than 375 publications. His specific research interests include Graves' disease, Hashimoto's thyroiditis and thyroid cancer.
Dr. Burman collaborated on the publication of the first comprehensive guidelines for the treatment and management of anaplastic thyroid cancer. He has also received many prestigious appointments and honors, including both the Van Meter Prize and the Paul Starr Prize, awarded by the American Thyroid Association (ATA) for excellence in research. He has served as president of the ATA and has received a Master designation from the American College of Physicians.
Dr. Burman serves as an editorial board member of Thyroid and is deputy editor of the Journal of Clinical Endocrinology and Metabolism. He also reviews for numerous other journals and has served on the U.S. Food and Drug Administration's Endocrine Advisory Committee.
Throughout his career, Dr. Burman has held leadership roles in and significantly contributed to committees for the Endocrine Society and the ATA. He has also been chair of the ATA Public Health Committee. Dr. Burman is frequently invited to lecture at medical schools, symposiums and conferences around the country and worldwide.
Dr. Burman graduated from the University of Missouri Medical School. He completed an Internal Medicine residency at Barnes Hospital (Washington University, St. Louis, MO) in 1972, and an Endocrinology fellowship at Walter Reed Army Medical Center (WRAMC) in 1974. During his tenure at WRAMC, he served as chief of Endocrinology, consultant in Endocrinology to the Surgeon General, as well as chair of Endocrinology and professor of Medicine at USUHS. Upon retirement from the Army in 1994, Dr. Burman joined Hospital Center.
Alternate Treatment Options
As research continues, there is a focus on finding treatment options for patients who do not respond positively to initial treatment plans. For those patients with advanced differentiated thyroid cancer, there may be a new treatment option. Read more...
Dr. Burman, in collaboration with Leonard Wartofsky, MD, and other clinicians at MedStar Washington Hospital Center, led a Phase II study investigating the use of sunitinib, part of the tyrosine kinase inhibitors (TKI) class of medications, as a treatment for those patients with advanced differentiated thyroid cancer that did not respond to earlier treatment methods.
As a Phase II study, the drug is given to a larger group of people with the intended disease to see if it is effective and to further evaluate its safety. This study evaluated the treatment option in tried in patients whose thyroid cancer continued to progress after application of first-line treatments (in the case of differentiated thyroid cancer, the first line treatment is surgery and radioactive iodine therapy).
The study found that sunitinib caused a statistically significant impact on anti-tumor activity in patients. The patients in the trial had a median progression-free survival rate of nearly 250 days. Sunitinib is an oral, small-molecule, multitargeted TKI, which has already been approved by the U.S. Food and Drug Administration (FDA) for some other types of cancer.